Psychedelics Today8 Des 2016

Gabby Agin-Liebes - Can Psilocybin Help Ease Anxiety & Depression for Those Who Are Facing Death?

Download It has been a big week for psychedelic research. Psilocybin and MDMA have made national headlines. The New York Times article, "F.D.A. Agrees to New Trials for Ecstasy as Relief for PTSD Patients," highlights the recent win for MAPS in regards to their MDMA-assisted psychotherapy research. The FDA has given MAPS the green light to pursue phase 3 research for MDMA-assisted psychotherapy for post-traumatic stress disorder. The New York Times also highlights the recent publications of psilocybin research in the article, "A Dose of a Hallucinogen from a 'Magic Mushroom,' and Then Lasting Peace." Psilocybin has been being researched by various institutions, including NYU and John Hopkins, for its potential therapeutic benefit to combat end-of-life anxiety due to terminal illness and cancer. The study results are fascinating: At the 6.5-month follow-up, psilocybin was associated with enduring anxiolytic and anti-depressant effects (approximately 60–80% of participants continued with clinically significant reductions in depression or anxiety), sustained benefits in existential distress and quality of life, as well as improved attitudes towards death. The psilocybin-induced mystical experience mediated the therapeutic effect of psilocybin on anxiety and depression. (http://m.jop.sagepub.com/content/30/12/1165.full) In this episode, Joe and Kyle chat with, Gabby Agin-Liebes, a co-author of the psilocybin study quoted above and a PhD student studying clinical psychology. During the conversation, we get into topics about the recent publication:

Formation of the NYU study
Gabby's role in the study
How volunteers were selected
Inclusion and admission criteria
Study results
Can psilocybin help those who are facing death?
Mystical experiences facilitating and mediating change in depression and anxiety
Current research that Gabby is part of and co-leading
How to get involved in the psychedelic field
Dreams and visions for the future of psychedelics and psychedelic research

About Gabrielle Agin-Liebes: Ms. Agin-Liebes is completing her training toward a PhD in clinical psychology at Palo Alto University. She is a member of PAU's Early Intervention Clinic clinical research laboratory, which provides and evaluates evidence-based treatments to prevent trauma-related problems in recently traumatized individuals. As part of this research laboratory, Ms. Agin-Liebes is examining the effects of trait self-compassion on trauma-related guilt cognitions. Through a supplemental practicum, Gabrielle is training toward a teacher certification in insight oriented mindfulness meditation through the Inner Resources Center at Palo Alto University. Ms. Agin-Liebes' other research focuses on novel and progressive psychotherapies for a variety of clinical indications, with areas of specialty in anxiety, depressive and traumatic stress disorders precipitated by life threatening illnesses. Through the University of California San Francisco (UCSF) Ms. Agin-Liebes is co-leading the qualitative investigation of a pilot study examining the safety and feasibility of Psilocybin-Assisted Supportive-Expressive Group Psychotherapy for demoralization and existential distress in older individuals living with HIV. Prior to beginning her graduate studies, Gabrielle served as Project Manager of the NYU School of Medicine (NYUSoM) Psychedelic Research Laboratory led by Stephen Ross MD in the Department of Psychiatry, where she oversaw the day-to-day operations of trials exploring psilocybin as a treatment for existential distress in cancer patients, and ketamine as a rapidly-acting antidepressant in Emergency Department patients, Through the NYU School of Medicine lab, she has received funding to investigate the qualitative experiences of participants undergoing psilocybin treatment for alcohol dependence and is helping to design a qualitative trial of religious leaders receiving psilocybin at NYUSoM and Johns Hopkins University (JHU). Ms. Agin-Liebes' other research interests include the role of self-compassion in addiction recovery and the therapeutic applications of meditation and mindfulness.

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(778)

PT 660 - Josh Lipson & Roman Palitsky: Psychedelic Harms and the Post-Psychedelic Challenges Study

This is an important discussion about harms, and what we should be doing about them. Josh and Roman are working on a major study at Emory University to answer some of the basic and outstanding questio...

12 Aug 1h 12min

PT 659 - Megan Bowers & Mikayla Hellwich

This is a special episode featuring two of our favorite organizations. DanceSafe and Shulgin Foundation. Listen to Joe Moore record with the heads of these orgs and learn about how you may be able to ...

5 Aug 1h 20min

PT 658 - Mareesa Stertz – Sphinx Gate Beyond Burning Man: Psychedelic Healing Without Psychedelics

My friend Mareesa joins us again on PT to discuss art, integration, psychedelic experiences without drugs, the heros journey and her smaller sphinxes that may start touring the country! Enjoy! Here ar...

31 Jul 1h 15min

PT 657 - Rachel Turetzky PhD & Douglas S. Wingate DTCM: The Eight-Circuit Model, Metaprogramming, and Psychedelic Therapy

Kyle and Joe interview Rachel Turetzky & Douglas S. Wingate about their perspectives on the Wilson\Leary 8 Circuit Model of consciousness. They recently released a CE approved program on Psychedelic E...

23 Jul 1h 18min

PT 656 - Travis Tyler Fluck: Denver Mushroom Decriminalization, Mutual Aid, and the Future of Psychedelic Culture

Denver mushroom decriminalization changed the national conversation around psilocybin access, personal use, and grassroots psychedelic reform. In this episode of Psychedelics Today, Joe Moore speaks w...

11 Mai 1h 43min

PT 655 - Martha Hammel and Tasia Poinsatte - Aspen Psychedelic Symposium

Aspen Psychedelic Symposium is the focus of this conversation with Martha Hammel of the Aspen Psychedelic Resource Center and Tasia Poinsatte of Healing Advocacy Fund. They join Joe Moore to discuss t...

8 Mai 54min

PT 654 - Erica Rex - Seeing What Is There

Seeing What Is There is at the center of this conversation with journalist and author Erica Rex, who joins Joe Moore to discuss her book Seeing What Is There: My Search for Sanity in the Psychedelic E...

23 Apr 1h 20min

PT 653 - Dr. Michael Alpert and Peter Alberding - ALS, Existential Distress, and Ketamine Therapy

ALS and ketamine therapy are at the center of this conversation with psychiatrist Dr. Michael Alpert and Peter Alberding, who was diagnosed with ALS in late 2023. Alpert is a Boston-area psychiatrist ...

16 Apr 1h 19min